MicroPort reveals results of trial comparing DES to Abbott’s Xience devices
MicroPort Scientific reported today that its Firehawk sirolimus-eluting stent met the 12-month primary endpoint of the company’s Target All-Comers trial, proving non-inferior to Abbott’s Xience drug-eluting stent.
The Target AC trial enrolled 1,654 patients at clinical sites around Europe. The study’s primary endpoint was the target lesion failure rate at 12 months. Patients participating in the trial will be followed for five years following implantation, according to MicroPort.
“Data from the Target AC trial, which included the most complex patient real-world population in Europe, demonstrated exceptional performance and safety of the Firehawk stent,” principal investigator Dr. William Wijns said in prepared remarks. “With this European clinical data set, Firehawk has the potential to positively impact patient care by further reducing the risk of late adverse events and the need for device-mandated prolonged dual antiplatelet therapy, which is often associated with a higher risk of bleeding as well as increased patient treatment cost.”
The 12-month target lesion failure rate for patients treated with the Firehawk stent was 6.1% compared to a 5.9% rate for the Xience group. MicroPort also noted that the ischemia-driven target lesion revascularization rate was lower in the Firehawk group (1.2%) compared to the Xience group (2.4%).
“The remarkably low rates of target lesion revascularization at one year confirm the favorable outcomes associated with the innovative Firehawk stent design,” Ming Zheng, VP of clinical science & medical affairs, added.
